- Home
- CLDX vs GPCR Comparison
CLDX vs GPCR Comparison
Compare CLDX & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLDX | GPCR |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CLDX | GPCR |
|---|---|---|
| Price | $29.27 | $41.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $46.60 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 692.1K | 640.1K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,743,000.00 | N/A |
| Revenue This Year | $111.39 | N/A |
| Revenue Next Year | $235.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $19.52 | $15.80 |
| 52 Week High | $35.83 | $94.90 |
Technical Indicators
Market Signals| Indicator | CLDX | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 53.61 |
| Support Level | $28.55 | $30.82 |
| Resistance Level | $30.90 | $57.23 |
| Average True Range (ATR) | 1.04 | 1.94 |
| MACD | -0.20 | 0.58 |
| Stochastic Oscillator | 22.48 | 96.26 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.